Skip to main content
. 2014 Oct 15;24(6):791–801. doi: 10.1089/scd.2014.0174

FIG. 2.

FIG. 2.

AdIGF-I-MSCs antifibrotic effects are, at least, comparable to AdGFP-MSCs treatment. (A–E) Representative pictures showing picrosirius red staining on liver sections derived from saline (A), AdGFP-MSCs (B), AdIGF-I-MSCs (C), AdGFP-MSCs+rIGF-I (D), or recombinant IGF-I (rIGF-I)-treated animals (E). (F) Quantification of collagen deposits based on sirius red staining. (G–K) Representative pictures showing α-SMA immunostained area on liver sections derived from saline (G), AdGFP-MSCs (H), AdIGF-I-MSCs (I), AdGFP-MSCs+rIGF-I (J), or rIGF-I-treated mice (K). (L) Quantification of α-SMA immunostained area. Scale bars: 50 μm. *στP<0.05; σσττδδP<0.01; ***P<0.001; ****P<0.0001; * versus saline; σ versus AdGFP-MSCs; τ versus AdGFP-MSCs+rIGF-I; δ versus rIGF-I.